Manufacturing, latest filing in 2026

Aktis Oncology, Inc. IPO

Aktis Oncology, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-19. It has amended it 2 times. It filed its final prospectus on 2026-01-09, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Select Market under the trading symbol “AKTS.”From the 424B4 filed 2026-01-09

We are offering 17,650,000 shares of our common stock.From the 424B4 filed 2026-01-09

The public offering price is $18.00 per share.From the 424B4 filed 2026-01-09

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents to:From the 424B4 filed 2026-01-09

Our net losses for the nine months ended September 30, 2025 and 2024 were $48.6 million and $31.9 million, respectively.From the S-1/A filed 2026-01-07

Swipe the table sideways to see every column.

Attovia Therapeutics, Inc. IPO

Attovia Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-14. It has amended it 2 times. It filed its final prospectus on 2026-08-05, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Market under the symbol “ATTO.”From the 424B4 filed 2026-08-05

We are offering 17,000,000 shares of our common stock.From the 424B4 filed 2026-08-05

The initial public offering price is $17.00 per share.From the 424B4 filed 2026-08-05

We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance the clinical development of ATTO-1310, ATTO-2306, and our research pipeline, including ATTO-1091, for other research and development activities, as well as for working capital and for other general corporate purposes.From the 424B4 filed 2026-08-05

For the years ended December 31, 2024 and 2025, we reported a net loss of $39.8 million and $60.6 million, respectively, and for the three months ended March 31, 2025 and 2026, we reported a net loss of $15.2 million and $18.7 million, respectively.From the S-1/A filed 2026-08-04

Swipe the table sideways to see every column.

Buda Juice, Inc. IPO

Buda Juice, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-08-27. It has amended it 7 times. It filed its final prospectus on 2026-01-08. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our Common Stock has been approved for listing on the NYSE American (“NYSE American”) under the symbol “BUDA”.From the 424B4 filed 2026-01-08

We currently estimate that the offering price of the Common Stock sold in the Offering will be between $7.50 and $9.00 per share.From the S-1/A filed 2026-01-06

However, we currently intend to use the net proceeds we receive from this Offering as follows:From the 424B4 filed 2026-01-08

For the year ended December 31, 2024, our net income was $3.5 million, representing a margin of 32% and a 58% increase from our net income of $2.2 million and a margin of 24% for the year ended December 31, 2023.From the S-1/A filed 2026-01-06

Swipe the table sideways to see every column.

Cortigent, Inc. IPO

Cortigent, Inc. has a Form S-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-16. Amendments on record here: 9. As of its latest filing, on 2026-05-13, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to have our common stock listed on NYSE American (“NYSE”) under the symbol “CRGT”.From the S-1/A filed 2026-05-13

We intend to use net proceeds from this offering primarily to conduct Orion research studies, convert the Orion prototype into a market-ready device for use in the pivotal clinical trial, conduct research for and initiate an early feasibility study of our Stroke Recovery System, manufacture Orion and stroke recovery devices for clinical studies, and to repay amounts owed to our parent Vivani and for working capital.From the S-1/A filed 2026-05-13

For the three months ended March 31, 2026 and the fiscal years ended December 31, 2025 and 2024, Cortigent generated no revenue from operations and incurred a net loss of $0.8 million, $3.1 million and $2.2 million, respectively.From the S-1/A filed 2026-05-13

Swipe the table sideways to see every column.

Global Thrive Fulfill Group Inc IPO

Global Thrive Fulfill Group Inc filed a Form S-1 registration statement for an initial public offering on 2025-07-03. It asked for the registration statement to be withdrawn on 2026-05-29. Each fact below is quoted from the filing named with it.

We have applied to list our common stocks on the Nasdaq Capital Market under the symbol “HSFZ”.From the S-1 filed 2025-07-03

We are offering 4,000,000 ordinary shares of the Company pursuant to this Offering.From the S-1 filed 2025-07-03

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Global Thrive Fulfill Group Inc , a corporation incorporated under the laws of California (the “ Company ”), hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Company’s registration statement on Form S-1 (File No. 333- 288499 ), initially filed with the Commission on July 3, 2025 (together with all exhibits thereto, the “ Registration Statement ”).From the RW filed 2026-05-29

Swipe the table sideways to see every column.

Hemab Therapeutics Holdings, Inc. IPO

Hemab Therapeutics Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-04-10. It has amended it 3 times. It filed its final prospectus on 2026-05-01, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “COAG.”From the 424B4 filed 2026-05-01

This is the initial public offering of shares of common stock of Hemab Therapeutics Holdings, Inc. We are offering 16,750,000 shares of our common stock.From the 424B4 filed 2026-05-01

The initial public offering price per share is $18.00.From the 424B4 filed 2026-05-01

We intend to use the net proceeds to us from this offering, together with our existing cash, cash equivalents, and marketable securities, to fund clinical development of sutacimig for the treatment of Glanzmann thrombasthenia and Factor VII deficiency and HMB-002 for the treatment of Von Willebrand Disease; additional discovery, preclinical, and clinical activities for current and future programs; and the remainder for working capital and other general corporate purposes.From the 424B4 filed 2026-05-01

Our net losses were $48.7 million and $63.9 million for the years ended December 31, 2024 and 2025, respectively.From the S-1/A filed 2026-04-30

Swipe the table sideways to see every column.

KLA-iBotics Holdings Ltd IPO

KLA-iBotics Holdings Ltd filed a Form F-1 registration statement for an initial public offering on 2026-05-29. As of its latest filing, on 2026-05-29, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

Reitar Logtech was listed on the Nasdaq Capital Market in 2024, with its class A ordinary shares trading under the symbol “RITR.” After a series of reorganization in 2025 and before the acquisition of Jingxing Holdings Limited (“ Jingxing Holdings ”) in May 2025, Kamui Logistics became a wholly-owned subsidiary of our Company, which itself is indirectly wholly-owned by Reitar Logtech which indirectly holds 3,000 Class B Ordinary Shares.From the F-1 filed 2026-05-29

The offering price of our Class A Ordinary Shares in this offering is expected to be between $4.00 and $6.00 per share.From the F-1 filed 2026-05-29

We plan to use the net proceeds of this offering as follows:From the F-1 filed 2026-05-29

For the two years ended March 31, 2025 and 2024 and the six months ended September 30, 2025, we generated revenue of approximately HK$35.3 million, HK$27.0 million and HK$15.8 million, respectively.From the F-1 filed 2026-05-29

Swipe the table sideways to see every column.

Kokobots Group IPO

Kokobots Group filed a Form F-1 registration statement for an initial public offering on 2025-07-11. It has amended it 2 times. As of its latest filing, on 2026-01-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to have our Class A ordinary shares listed on the Capital Market of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “KOKO.” We cannot guarantee that we will be successful in listing our Class A ordinary shares on Nasdaq; however, we will not complete this offering unless we are so listed.From the F-1/A filed 2026-01-23

We are offering 3,750,000 Class A ordinary shares.From the F-1/A filed 2026-01-23

We intend to use the net proceeds of this offering for marketing and promotional activities, product upgrades and development and working capital.From the F-1/A filed 2026-01-23

During the years ended June 30, 2025 and 2024, our revenues were approximately $4.5 million and $4.0 million, respectively, and net income was approximately $0.9 million and $1.0 million, respectively.From the F-1/A filed 2026-01-23

During the years ended June 30, 2025 and 2024, our revenues were approximately $4.5 million and $4.0 million, respectively, and net income was approximately $0.9 million and $1.0 million, respectively.From the F-1/A filed 2026-01-23

Swipe the table sideways to see every column.

Latigo Biotherapeutics, Inc. IPO

Latigo Biotherapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-17. It has amended it 2 times. It filed its final prospectus on 2026-08-07, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “LTGO”.From the 424B4 filed 2026-08-07

This is an initial public offering of shares of common stock of Latigo Biotherapeutics, Inc. We are offering 19,200,000 shares of our common stock to be sold in this offering.From the 424B4 filed 2026-08-07

The initial public offering price is $18.00 per share.From the 424B4 filed 2026-08-07

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, (i) to advance the development of LTG-001 through Phase 3 bunionectomy and open-label safety topline results and to NDA submission, as well as commercial readiness, (ii) to advance the development of LTG-321 through Phase 2 osteoarthritis pain proof of concept topline results and the start of Phase 3 clinical development, and (iii) for other research and development activities, including the development of LTG-418, as well as for working capital and other general corporate purposes.From the 424B4 filed 2026-08-07

For the years ended December 31, 2024 and 2025, our net losses were approximately $61.2 million and $109.2 million, respectively, and our accumulated deficit as of March 31, 2026 was approximately $266.1 million.From the S-1/A filed 2026-08-04

Swipe the table sideways to see every column.

Lyntris Inc. IPO

Lyntris Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-23. It has amended it 3 times. It filed its final prospectus on 2026-08-19, at a public offering price of $17.50 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our common stock on the NYSE under the symbol “LYNX.”From the 424B4 filed 2026-08-19

We are offering 4,878,049 shares of common stock and the selling stockholders identified in this prospectus are offering an additional 19,121,951 shares of common stock.From the S-1/A filed 2026-08-12

• the initial public offering price of $17.50 per share of our common stock;From the 424B4 filed 2026-08-19

We intend to use the net proceeds from this offering to repay approximately $60.0 million outstanding under our New Credit Facility.From the 424B4 filed 2026-08-19

During the six months ended June 30, 2026 and 2025, our revenue was $241.0 million and $179.1 million.From the S-1/A filed 2026-08-12

We reported net losses of approximately $13.0 million, $9.7 million and $11.8 million for the six months ended June 30, 2026, the six months ended June 30, 2025 and the twelve months ended June 30, 2026, respectively.From the S-1/A filed 2026-08-12

Swipe the table sideways to see every column.

Nintech Mould Factory Inc. IPO

Nintech Mould Factory Inc. filed a Form F-1 registration statement for an initial public offering on 2026-05-26. As of its latest filing, on 2026-05-26, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have reserved the symbol “NTMJ” for the purpose of listing our Class A Ordinary Shares on the Nasdaq Capital Market, or the Nasdaq.From the F-1 filed 2026-05-26

This is an initial public offering of 6,250,000 Class A ordinary shares, par value $0.0001 per share (each, a “Class A Ordinary Share,” collectively, “Class A Ordinary Shares”), of Nintech Mould Factory Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company” or “Nintech,” and when referring to the consolidated company including our subsidiaries, “we” or “us”).From the F-1 filed 2026-05-26

We plan to use the net proceeds we receive from this offering for upgrade and purchase of manufacturing equipment, expansion of manufacturing facilities, research and development, and general corporate purposes and working capital.From the F-1 filed 2026-05-26

We generate revenues of $18.7 million for the year ended December 31, 2025 and $15.5 million for the year end December 31, 2024, representing an annual growth of $3.1 million, or 20.1%.From the F-1 filed 2026-05-26

Swipe the table sideways to see every column.

Seaport Therapeutics, Inc. IPO

Seaport Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-04-10. It has amended it 1 time. It filed its final prospectus on 2026-05-01, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “SPTX.”From the 424B4 filed 2026-05-01

This is an initial public offering of shares of common stock of Seaport Therapeutics, Inc. We are offering 14,160,000 shares of our common stock.From the 424B4 filed 2026-05-01

The initial public offering price is $18.00 per share.From the 424B4 filed 2026-05-01

We intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents, and investments, to advance development of GlyphAllo TM (SPT-300), GlyphAgo TM (SPT-320), and Glyph2BLSD TM (SPT-348), as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purposes.From the 424B4 filed 2026-05-01

Our net losses totaled $74.9 million and $46.9 million for the years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-04-27

Swipe the table sideways to see every column.

Suchness Tech Ltd IPO

Suchness Tech Ltd filed a Form F-1 registration statement for an initial public offering on 2026-05-12. It has amended it 2 times. As of its latest filing, on 2026-08-03, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to have our Class A Ordinary Shares listed on the Nasdaq Capital Market (“Nasdaq”) and have reserved the symbol “SUCH” for purposes of listing our Class A Ordinary Shares on Nasdaq.From the F-1/A filed 2026-08-03

This is an initial public offering of 5,000,000 class A ordinary shares of par value of US$0.0001 each (“Class A Ordinary Shares”) of SUCHNESS TECH LIMITED.From the F-1/A filed 2026-08-03

We plan to use the net proceeds we receive from this offering in the following manner:From the F-1/A filed 2026-08-03

Our total cost of revenues decreased by $1,164,098 or 13.0% from $8,961,038 for the six months ended December 31, 2024 to $7,796,940 for the six months ended December 31, 2025, which was generally due to the significant decrease in revenue.From the F-1/A filed 2026-08-03

As a result of the reasons and circumstances discussed above, our net income decreased by $2,312,425, or 58.4%, from $3,960,141 for the six months ended December 31, 2024 to $1,647,716 for the six months ended December 31, 2025.From the F-1/A filed 2026-08-03

Swipe the table sideways to see every column.

SunHo BioTech Group Ltd IPO

SunHo BioTech Group Ltd filed a Form F-1 registration statement for an initial public offering on 2025-09-11. It has amended it 3 times. As of its latest filing, on 2026-01-22, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We intend to list our Class A Ordinary Shares on the NYSE American under the symbol “SGSH.” The closing of this offering is conditioned upon NYSE American’s final approval of our listing application, and there is no guarantee or assurance that our Class A Ordinary Shares will be approved for listing on NYSE American.From the F-1/A filed 2026-01-22

We intend to use the net proceeds from this Offering for mergers and acquisitions (the Company has not identified any target as of the date of this prospectus); research and development, such as enhancement of R&D equipment; marketing; and operations and general working capital .From the F-1/A filed 2026-01-22

Revenue increased by S$2,529,068 or 197% to S$3,810,202 for the six months ended June 30, 2025.From the F-1/A filed 2026-01-22

For the years ended December 31, 2024, the Company reported net losses of S$2,770,705 (2023:From the F-1/A filed 2026-01-22

Swipe the table sideways to see every column.

Varsal Tech, Inc. IPO

Varsal Tech, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-05-26. It has amended it 3 times. As of its latest filing, on 2026-08-17, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We plan to apply to list our Class A Common Stock on the NYSE American and intend to reserve the symbol “VAT” for purposes of listing our Class A Common Stock on the NYSE American.From the S-1/A filed 2026-08-17

We plan to use the net proceeds we receive from this offering to fund working capital and for other general corporate purposes, including the support of our current business and:From the S-1/A filed 2026-08-17

For the nine months ended June 30, 2026, cash provided by operating activities was primarily driven by net income of $6.8 million, partially offset by changes in operating assets and liabilities that used $0.5 million of cash, mainly reflecting an increase in accounts receivable, partially offset by increases in accounts payable, income tax payable, and other payables and accrued liabilities, as well as a decrease in inventories.From the S-1/A filed 2026-08-17

Swipe the table sideways to see every column.

Veradermics, Inc IPO

Veradermics, Inc filed a Form S-1 registration statement for an initial public offering on 2026-01-09. It has amended it 1 time. It filed its final prospectus on 2026-04-30. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

The newest 12 of 16 records.

Our common stock is listed on the NYSE under the symbol “MANE.”From the S-1 filed 2026-08-07

We are offering 3,843,790 shares of our common stock in this offering.From the 424B4 filed 2026-04-30

We expect that the initial public offering price will be between $14.00 and $16.00 per share of our common stock.From the S-1/A filed 2026-01-28

We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance VDPHL01 through NDA approval and initial commercialization in the United States, if approved.From the 424B4 filed 2026-02-04

Our net losses for the nine months ended September 30, 2025 and 2024 were $48.1 million and $20.8 million, respectively.From the S-1/A filed 2026-01-28

Swipe the table sideways to see every column.

Vogenx, Inc. IPO

Vogenx, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-15. It has amended it 2 times. It filed its final prospectus on 2026-08-12, at a public offering price of $13.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Capital Market under the symbol “VOGX.”From the 424B4 filed 2026-08-12

We are offering 6,250,000 shares of our common stock.From the 424B4 filed 2026-08-12

The initial public offering price is $13.00 per share.From the 424B4 filed 2026-08-12

We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund the continued development of mizagliflozin, payment of accrued expenses and for additional research and development, general corporate purposes and working capital.From the 424B4 filed 2026-08-12

Our net loss was $2.2 million and $1.4 million for the years ended December 31, 2024 and 2025, respectively.From the S-1/A filed 2026-08-10

Swipe the table sideways to see every column.

XINXU COPPER INDUSTRY TECHNOLOGY Ltd IPO

XINXU COPPER INDUSTRY TECHNOLOGY Ltd filed a Form F-1 registration statement for an initial public offering on 2026-01-26. It has amended it 7 times. It asked for the registration statement to be withdrawn on 2026-05-06. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Capital Market of The Nasdaq Stock Market LLC (the “Nasdaq”) under the symbol “XXC.” We cannot guarantee that we will be successful in listing our ordinary shares on Nasdaq; however, we will not complete this offering unless we are so listed.From the F-1/A filed 2026-02-11

We are offering 3,000,000 ordinary shares, par value HK$0.0005 per share, on a firm commitment basis.From the F-1/A filed 2026-02-11

For the fiscal years ended June 30, 2025 and 2024, we recognized revenue of approximately $113.46 million and $105.87 million, respectively, and generated net income of approximately $1.33 million and $0.84 million, respectively, for the fiscal year ended June 30, 2025 and 2024.From the F-1/A filed 2026-02-11

For the fiscal years ended June 30, 2025 and 2024, we recognized revenue of approximately $113.46 million and $105.87 million, respectively, and generated net income of approximately $1.33 million and $0.84 million, respectively, for the fiscal year ended June 30, 2025 and 2024.From the F-1/A filed 2026-02-11

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), on behalf of Xinxu Copper Industry Technology Limited (“we,” “us,” “our,” or the “Company”), we hereby submit this letter to notify the Securities and Exchange Commission (the “Commission”) of our withdrawal of our Registration Statement on Form F-1 (File No. 333-278407) (the “Registration Statement”), because the Company has elected not to proceed with the registration of the securities contemplated by the Registration Statement at this time.From the RW filed 2026-05-06

Swipe the table sideways to see every column.

Yellowstone Midco Holdings II, LLC IPO

Yellowstone Midco Holdings II, LLC filed a Form S-1 registration statement for an initial public offering on 2025-11-17. It has amended it 3 times. It filed its final prospectus on 2026-01-30. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our common stock on the New York Stock Exchange (“NYSE”), under the symbol “YSS.”From the 424B4 filed 2026-01-30

We are offering 18,500,000 shares of common stock.From the 424B4 filed 2026-01-30

We anticipate that the initial public offering price for our common stock will be between $30.00 and $34.00 per share.From the S-1/A filed 2026-01-26

We intend to use the net proceeds we receive from this offering for working capital to fund growth and other general corporate purposes, which may include building inventory and capital expenditures.From the 424B4 filed 2026-01-30

We experienced net losses of $98.9 million and $29.7 million for the years ended December 31, 2024 and 2023, respectively, and net losses of $56.0 and $73.6 for the nine months ended September 30, 2025 and 2024, respectively.From the S-1/A filed 2026-01-26

Swipe the table sideways to see every column.